Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al..  2018.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.. N Engl J Med. 378(8):731-739.

Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A.  2017.  Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.. Oncotarget. 8(8):14017-14028.

Brown JA, Kinzig CG, DeGregorio SJ, Steitz JA.  2016.  Hoogsteen-position pyrimidines promote the stability and function of the MALAT1 RNA triple helix.. RNA. 22(5):743-9.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ et al..  2015.  CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.. Cancer Cell. 28(1):15-28.

Kim D-Y, Joo Y-D, Lim S-N, Kim S-D, Lee J-H, Lee J-H, Kim DHwan Denni, Kim K, Jung CWon, Kim I et al..  2015.  Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.. Blood. 126(6):746-56.

Dubrovsky L, Pankov D, Brea EJoseph, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA.  2014.  A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.. Blood. 123(21):3296-304.